EMA Authorised: MicardisPlus (telmisartan;hydrochlorothiazide) — Boehringer Ingelheim International GmbH

View source ↗

Summary

EMA authorised MicardisPlus (telmisartan with hydrochlorothiazide) by Boehringer Ingelheim International GmbH for the treatment of hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• HYDROCHLOROTHIAZIDE (hydrochlorothiazide)
• Telmisartan (Telmisartan)

Snippet

Status: Authorised. Therapeutic area: Hypertension. MAH: Boehringer Ingelheim International GmbH. Decision date: 29/03/2025